SAN DIEGO, April 10 /PRNewswire/ -- MedImmune today announced that researchers will present seven abstracts on the company's oncology portfolio programs at the Annual Meeting of the American Association for Cancer Research, exemplifying the company's long-standing commitment to excellence in oncology research.
"Cancer research has long been a core area of focus at MedImmune and we are proud to share data from our increasingly large oncology portfolio at this year's meeting," said Bahija Jallal, Ph.D., vice president of translational science and head, preclinical oncology.
Investigators will present results from four studies of the novel heat
shock protein 90 (Hsp90) inhibitor retaspimycin hydrochloride (also known
as IPI-504); two studies of antibodies targeting the CD19 antigen,
including MEDI-538 (also known as MT103); and one study of monocyte
chemotactic protein-1 (MCP-1).
MedImmune research scheduled to be presented includes:
-- IPI-504, a Novel Hsp90 Inhibitor is Effective in EGFR T790M and
non-T790M Gefitinib-Resistant Lung Cancer Cell Lines (Oral
Presentation: Histone Deacetylase and Heat Shock Protein Inhibitors,
abstract 2450) - Joon O. Park, M.D., Monday, April 14 from 11:55 a.m.
- 12:10 p.m. in Room 24A-C.
-- Pharmaceutical Development of IPI-504, an Aqueous Soluble Analog of
17-AAG and Potent Inhibitor of Hsp90 (Educational Session: From
Chemistry to the Clinic: Pathways for Drug Discovery and Development
- Part 4: Chemical Development: Translating a Potent Agent into a
Registered Product) - James R. Porter, Ph.D., Saturday, April 12 from
4:15 - 4:40 p.m. in Ballroom 20D.
-- IPI-504, a Selective Inhibitor of Hsp90, Exhibits Potent Anti-Tumor
Activity Against Metastatic Melanoma Cell Lines that Harbor B-Raf or
N-Ras Mutations (Poster Session: Pharmacology and Pharmacodynamics,
abstract 4764, post
Copyright©2008 PR Newswire.
All rights reserved